Slide 1: Acting FSGS Clinical Study Licensing Webinar
ACTING FSGS CLINICAL STUDY @ Dimerix (ASX:DXB) y 27 May 2024 icensing Webinar onal use onl or pers | Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs Authorised for lodgement by the Board of the Company
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown c Gisks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different f
Slide 3: Lead drug candidate, FSGS indication, market opportunity, milestones
Lead Drug Candidate • For personal use only • FSGS Indication • • • Market Opportunity • • • o Commercial Validation • • Upcoming FSGS Milestones • •
Slide 4: Taiba - Experts in rare disease medicines
«% taiba — Experts in rare disease medicines access rare >Jaiba brings extensive experience in registration & commercialisation of rare disease products [< D n 5 ~ Established commercial ris presence in the United Arab |“ Emirates (UAE), Saudi Arabia, [= Oman, Kuwait, Qatar, Bahrain O and Ira iq y)
Slide 5: Dimerix and Taiba - strategic partners in rare disease
wo Dimerix /v% taiba- strategic partners in rare disease access rare > CWe are thrilled to partner with Dimerix in launching DMX-200 in the Middle East pending FDA Cdpproval. DMX-200 will strengthen our portfolio of treatments for rare nephrology diseases, (pnabling us to offer a comprehensive solut
Slide 6: Key elements of Taiba partnership
Key elements of «% taiba partnership access rare Taiba acquires exclusive license to commercialise DMX-200 for kidney disease the United Arab Emirates (UAE), Saudi Arabia, Oman, Kuwait, Qatar, Bahrain and Iraq | use only Dimerix to receive up to “AU$120.5* million in upfront and milestone payments,
Slide 7: Summary of licensing deals (DMX-200)
Summary of licensing deals (DMX-200) Dimerix has validated the technology! and proven its ability to licence multiple territories, with more deals anticipated Summary Advanz Pharma? Other Licensing Deals (incl. US & China) For personal use sales EEA, Canada, United Arab Emirates (UAE), ) Territories
Slide 8: Global partnering availability
Global partnering availability + Licensing deal second of potentially multiple agreements globally + Received multiple non-binding term sheets for global deals and regional deals! + Multiple parties in data room conducting due diligence and negotiating for various territories! 9 avtovrs [REPAGERMANI
Slide 9: Potential FSGS market size
Potential FSGS market size Estimated 7MM (+China) No approved therapies for F diagnosed patients (2022)'4 Multi-billion dollar market potential a A >303,000 patients Example pricing for other rare kidney disease drugs : * in the US (i.e. Filspari in IgAN)?is US$9,900 p/month * in Europe/UK (i.e. Kin
Slide 10: Background Phase Trial Timeline
For personal use only Background Phase 3 Trial Timeline • • •
Slide 11: Corporate overview
Corporate overview For personal use only days" Ticker Symbol ASX: DXB Proforma Cash Balance (Mar24) “A$35.2 million Market Capitalisation “A$187 million Share price ~A$0.34 Total ordinary shares on issue 549,674,633 Average daily liquidity for past 10 478 million SHARE PRICE Boa 8 sera ance os i * a
Slide 12: Lead drug candidate, FSGS indication, market opportunity, milestones
Lead Drug Candidate • For personal use only • FSGS Indication • • • Market Opportunity • • • o Commercial Validation • • Upcoming FSGS Milestones • •
Slide 13: Dimerix contact details
For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN ESG Statement le of. SCAN ME Dimeri